Renaud Ronald C JR 4

What Happened Renaud Ronald C Jr, CEO, President and a director of Kailera Therapeutics (KLRA), exercised options on 2026-06-09 to acquire 38,094 shares at an exercise price of $5.25 per share, for a total cash outlay of $199,994. The Form 4 also shows a related derivative entry disposing of 38,094 shares at $0, which reflects the conversion/settlement of the option into common stock.

Key Details

• Transaction date: 2026-06-09. Exercise (code M): 38,094 shares @ $5.25 = $199,994 (acquired). Matching derivative disposal: 38,094 shares @ $0 (derivative conversion).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Options vested 33% on Sep 9, 2025, with the remainder vesting in 24 substantially equal monthly installments, subject to continued service (per F1).
• Filing: Report filed 2026-06-11 for a 2026-06-09 transaction — filed within the normal two-business-day Form 4 window (timely).
• Transaction code explanation: M = Option exercise/conversion; the separate $0 disposal line represents the derivative being converted into issued shares.

Context This filing documents an option exercise (an acquisition of shares), not a sale. The filing does not indicate an immediate resale or a cashless exercise — the reported cash paid ($199,994) suggests the insider funded the exercise. The derivative disposal line is a technical reporting entry showing the option converted into the issued shares under the stated vesting schedule.